UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: TrimonilR-400mg-PRTablet-SE-AJ-MPD-BBDL

Trimonil Retard 400 mg Depottablett

MPID: SE-100000400-00012922
EURDID: 539

Full name: Trimonil Retard 400 mg Depottablett

- Invented Name Part: Trimonil Retard

- Strength part: 400 mg

- Pharmaceutical dose form part: Depottablett

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Prolonged-release tablet

Legal status of supply: Medicinal product subject to medical prescription

Domain: Human use

Resource status: Current

Product classification:

  • 100000097377 carbamazepine

Marketing Authorisation 1 of 1

Authorisation number: 12922

Region: Kingdom of Sweden

Marketing authorisation holder: Desitin Arzneimittel GmbH

Identifier:

  • LOC-100004783

Status: Valid (1997-05-23)

Package 1 of 1

PCID:

Description:
Blister, 100 tabletter

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 100 tablet

Package: 1 Box (Cardboard)

Containing:

Package: 10 Blister (Aluminium) (PolyVinyl Chloride)

Containing: 10 tablet

Manufactured Item

Dose form: Prolonged-release tablet

Unit of presentation: tablet

Ingredient

Role: Active

Substance: Carbamazepine

Presentation strength: 400 milligram(s) / 1 tablet

Reference strength:
Carbamazepine 400 milligram(s) / 1 tablet

Administrable Product (1 of 1)

Dose form: Prolonged-release tablet

Unit of presentation:

Route of administration:

  • Oral use

Ingredients:

Ingredient

Role: Active

Substance: Carbamazepine

Presentation strength: 400 milligram(s) / 1 tablet

Reference strength:
Carbamazepine 400 milligram(s) / 1 tablet